Nymox Pharmaceutical Corporation (NYM.MU)
- Previous Close
0.8600 - Open
0.8600 - Bid --
- Ask --
- Day's Range
0.8600 - 0.8600 - 52 Week Range
0.8600 - 0.8600 - Volume
1,000 - Avg. Volume
0 - Market Cap (intraday)
104.863M - Beta (5Y Monthly) 0.32
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.
nymox.comRecent News: NYM.MU
Performance Overview: NYM.MU
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NYM.MU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NYM.MU
Valuation Measures
Market Cap
26.23M
Enterprise Value
26.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
-5.23k
Enterprise Value/EBITDA
-17.67
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.51%
Return on Equity (ttm)
--
Revenue (ttm)
-5k
Net Income Avi to Common (ttm)
-4.87M
Diluted EPS (ttm)
-0.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
76k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-726.55k